NEW YORK — Chinese diagnostics firm AmoyDx said on Friday that it has partnered with AstraZeneca to develop a companion diagnostic for use in treating ovarian cancer patients with homologous recombination deficiency (HRD).
Specific terms of the deal were not disclosed.